Perzea 420mg Injection contains pertuzumab, a targeted anticancer medicine belonging to the class of HER2-targeted monoclonal antibodies. It is a recombinant DNA-derived (r-DNA origin) medicine used in combination with other anticancer treatments for certain types of HER2-positive breast cancer.

Perzea 420 mg works by binding to the HER2 receptor on cancer cells and blocking specific signals involved in cancer-cell growth and survival. It also interferes with the formation of signalling pathways that support tumour progression.

Perzea 420 mg is supplied as a concentrate for intravenous infusion in a single-dose vial containing 420 mg of pertuzumab in 14 mL, with a concentration of 30 mg/mL.

This medicine should only be administered under the supervision of an experienced oncologist. The treatment combination, dosage and schedule depend on the patient’s cancer type, stage, previous treatment and overall health.

How to Use Perzea 420 mg Injection

• Perzea 420 mg must be administered by a qualified healthcare professional.
• It is given through intravenous infusion after appropriate dilution.
• Do not administer it as an intravenous push or bolus.
• The usual initial loading dose of pertuzumab is 840 mg, followed by a maintenance dose of 420 mg every three weeks in commonly used treatment regimens.
• The 420 mg maintenance dose is administered according to the oncologist’s prescribed treatment schedule.
• Perzea may be given in combination with trastuzumab and chemotherapy, depending on the treatment indication.
• Patients should be monitored during and after infusion for possible reactions.
• Never attempt to prepare or administer this medicine without professional medical supervision.

Perzea 420 mg Injection Uses

Perzea 420 mg may be prescribed for the following conditions:

• HER2-Positive Early Breast Cancer: Used in combination with trastuzumab and chemotherapy for eligible patients receiving treatment before or after surgery.
• Locally Advanced Breast Cancer: May be included in treatment plans for certain patients with HER2-positive locally advanced or inflammatory breast cancer.
• HER2-Positive Metastatic Breast Cancer: Used with trastuzumab and chemotherapy in eligible patients whose cancer has spread or is locally recurrent and cannot be surgically removed.
• High-Risk Breast Cancer: May be considered as part of adjuvant treatment for eligible patients at increased risk of recurrence.

Treatment suitability depends on confirmed HER2-positive tumour status and the oncologist’s clinical assessment.

How Does Perzea 420 mg Work?

• HER2 Receptor Targeting: Pertuzumab binds to the HER2 receptor on cancer cells.
• Blocks Protein Signalling: It prevents HER2 from pairing with other HER family receptors, particularly HER3, interfering with signals involved in cancer-cell growth.
• Helps Control Tumour Growth: By blocking these signalling pathways, pertuzumab can help slow cancer progression.
• Supports Combination Therapy: It works through a different HER2-binding mechanism from trastuzumab, allowing both medicines to be used together in appropriate treatment regimens.
• Immune System Activity: Pertuzumab can also help the immune system recognise and attack targeted cancer cells.

Perzea 420 mg is a targeted cancer medicine and is not suitable for every type of cancer.

Perzea 420 mg Side Effects

Like other targeted oncology medicines, Perzea 420 mg may cause side effects. Commonly reported reactions include:

• Diarrhoea
• Nausea and vomiting
• Fatigue and weakness
• Hair loss
• Skin rash
• Reduced appetite
• Infusion-related reactions
• Muscle and joint discomfort
• Peripheral neuropathy
• Low white blood cell counts, particularly when used with chemotherapy

Serious adverse reactions may include left ventricular dysfunction, severe hypersensitivity reactions, anaphylaxis, and embryo-fetal toxicity.

Patients should immediately report breathing difficulties, chest discomfort, severe allergic reactions, unusual swelling or other concerning symptoms to their healthcare team.

Perzea 420 Drug Interactions

Inform your oncologist about all prescription medicines, over-the-counter medicines, supplements and other cancer treatments you are receiving.

Perzea 420 mg is commonly used alongside trastuzumab and chemotherapy in approved treatment regimens. Its combination with other medicines must be carefully evaluated by the treating specialist.

Perzea 420 mg During Pregnancy and Breastfeeding

Pertuzumab may cause harm to an unborn baby. Women who are pregnant, planning pregnancy or capable of becoming pregnant should discuss the risks and appropriate contraception with their oncologist.

Breastfeeding should be discussed with a healthcare professional before starting treatment. Follow the recommended precautions in the locally approved prescribing information.

Perzea 420 mg and Heart Function Monitoring

Pertuzumab-based treatment may affect heart function, particularly when used with other HER2-targeted medicines.

Doctors may assess left ventricular ejection fraction (LVEF) before and during treatment. Patients with a history of heart disease should inform their oncologist before receiving Perzea 420 mg.

Perzea 420 mg Injection Storage

• Store the medicine under refrigerated conditions as specified in the product packaging.
• The standard pertuzumab vial storage requirement is 2°C to 8°C.
• Keep the vial in its original carton to protect it from light.
• Do not freeze the medicine.
• Do not shake the vial.
• Maintain the required cold chain during transportation and distribution.
• Keep the medicine out of reach of children.

Always follow the specific storage and handling instructions supplied with the product.

Important Safety Information About Perzea 420 Injection

Perzea 420 mg is a prescription-only targeted anticancer medicine. It must be administered by trained healthcare professionals in a clinical setting equipped to manage infusion reactions and severe allergic reactions.

HER2 testing is required to establish treatment eligibility. Regular monitoring of heart function and overall treatment response may be necessary.

Do not start, stop, or change the treatment schedule without consulting your oncologist.

Frequently Asked Questions About Perzea 420 mg

1. What is Perzea 420 mg Injection used for?

Perzea 420 mg contains pertuzumab and is used with other anticancer medicines to treat certain types of HER2-positive breast cancer, including eligible early-stage and metastatic cases.

2. What is the active ingredient in Perzea 420 mg?

The active ingredient is pertuzumab, a recombinant DNA-derived humanised monoclonal antibody.

3. What is the strength of Perzea 420 mg Injection?

Perzea contains 420 mg of pertuzumab in a 14 mL single-dose vial, providing a concentration of 30 mg/mL.

4. Is Perzea 420 mg a chemotherapy medicine?

No. Pertuzumab is classified as a targeted cancer therapy and monoclonal antibody. However, it is commonly administered in combination with chemotherapy and other targeted medicines.

5. How is Perzea 420 mg administered?

It is administered through intravenous infusion by a qualified healthcare professional after appropriate dilution.

6. How often is Perzea 420 mg given?

A commonly used regimen includes an initial loading dose of 840 mg, followed by 420 mg every three weeks. The exact schedule is determined by the oncologist.

7. Can Perzea 420 mg be used alone?

Per approved treatment regimens, pertuzumab is generally used in combination with other anticancer medicines, such as trastuzumab and chemotherapy.

8. What are the common side effects of Perzea 420 mg?

Common side effects include diarrhoea, nausea, fatigue, hair loss, rash, reduced appetite and infusion-related reactions.

9. Does Perzea 420 mg require HER2 testing?

Yes. HER2 testing is essential to determine whether a patient’s breast cancer is suitable for pertuzumab-based treatment.

10. Does Perzea 420 mg affect heart function?

It may affect cardiac function. Doctors may monitor heart performance, including LVEF, before and during treatment.

11. How should Perzea 420 mg be stored?

It should generally be stored between 2°C and 8°C, protected from light, and should not be frozen or shaken. Follow the product-specific instructions.

12. Can Perzea 420 mg be used during pregnancy?

Pertuzumab may cause fetal harm. Pregnant patients or those planning pregnancy must discuss treatment risks with their oncologist.

13. Is Perzea 420 mg available as a single-dose vial?

Yes. The product packaging specifies one single-dose vial containing 420 mg/14 mL of pertuzumab concentrate.

14. Can Perzea 420 mg be administered at home?

It should be administered in an appropriate clinical setting by trained healthcare professionals who can manage infusion-related and allergic reactions.

15. Who should decide the Perzea 420 mg treatment schedule?

An experienced oncologist should determine the treatment schedule based on HER2 status, cancer stage, previous treatments and individual patient requirements.

Medical Disclaimer: This information is intended for educational and pharmaceutical product-information purposes only. It does not replace professional medical advice, diagnosis or treatment. Perzea 420 mg is a prescription oncology medicine and should only be used under the supervision of a qualified oncologist.